country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

58 Results for "

-MEK1/2

" in MedChemExpress (MCE) Product Catalog:

Products (58)

Sort by :

Categories

By Targets

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

103

Selumetinib

103 Publications Verification

Cat. No.: HY-50706

CAS No.: 606143-52-6

Synonyms: AZD6244; ARRY-142886

Target:

MEK Apoptosis

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. Selumetinib can penetrate the blood brain barrier (BBB) ^[1] .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

103

Selumetinib sulfate

103 Publications Verification

Cat. No.: HY-50706A

CAS No.: 943332-08-9

Synonyms: AZD6244 sulfate; ARRY-142886 sulfate

Target:

MEK Apoptosis

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Selumetinib (AZD6244) sulfate is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) sulfate inhibits ERK1/2 phosphorylation. Selumetinib sulfate can penetrate the blood brain barrier (BBB) ^[1] .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Binimetinib

56 Cited Publications

Cat. No.: HY-15202

CAS No.: 606143-89-9

Purity: 99.31%

Synonyms: MEK162; ARRY-162; ARRY-438162

Target:

MEK Autophagy

Research Areas:

Cancer

Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC₅₀ of 12 nM.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Idasanutlin

52 Cited Publications

Cat. No.: HY-15676

CAS No.: 1229705-06-9

Purity: 99.93%

Synonyms: RG7388

Target:

MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Pyroptosis Reactive Oxygen Species (ROS) Caspase

Research Areas:

Neurological Disease Cancer

Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC₅₀ of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors ^[1] ^[12].

Compare